Clinical Value and Limitations of Plasma p-tau217 in the Supplementary Diagnosis of Early Alzheimer's Disease

Early and accurate diagnosis of Alzheimer's disease (AD) is necessary to enable timely intervention. Some of the traditional tests, such as positron emission tomography (PET) scans and cerebrospinal fluid (CSF) punctures, are too expensive or invasive and thus not been widely used. This review systematically evaluates the clinical progress of research on plasma phosphorylated tau 217 (p-tau217). The aim is to know if p-tau217 can be used as an early marker for the start of mild cognitive impairment (MCI) in brains of older adults. According to the current data, plasma p-tau217 have good diagnostic ability for early-stage Alzheimer's disease and can be used in a "two-cutoff" method at the clinic. Therefore, non-AD patients do not need to be included in the primary care area, and high-risk individuals in special memory clinics can be identified to reduce the number of expensive PET and CSF tests. However, it still has many problems in clinical use. In short, although plasma p-tau217 is a promising non-invasive early detection method, healthcare professionals should still consider all the circumstances in the overall health status of each patient before making any decisions.

Authors

Institutions

Publication Details

Journal
Theoretical and Natural Science
Published
2026-11-17
DOI
https://doi.org/10.54254/2753-8818/2027.38943
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical Value and Limitations of Plasma p-tau217 in the Supplementary Diagnosis of Early Alzheimer's Disease

Anqi Gong
7 links
Theoretical and Natural Science
Dementia and Cognitive Impairment Research
article

Clinical Value and Limitations of Plasma p-tau217 in the Supplementary Diagnosis of Early Alzheimer's Disease

Anqi Gong
article en

Abstract

Early and accurate diagnosis of Alzheimer's disease (AD) is necessary to enable timely intervention. Some of the traditional tests, such as positron emission tomography (PET) scans and cerebrospinal fluid (CSF) punctures, are too expensive or invasive and thus not been widely used. This review systematically evaluates the clinical progress of research on plasma phosphorylated tau 217 (p-tau217). The aim is to know if p-tau217 can be used as an early marker for the start of mild cognitive impairment (MCI) in brains of older adults. According to the current data, plasma p-tau217 have good diagnostic ability for early-stage Alzheimer's disease and can be used in a "two-cutoff" method at the clinic. Therefore, non-AD patients do not need to be included in the primary care area, and high-risk individuals in special memory clinics can be identified to reduce the number of expensive PET and CSF tests. However, it still has many problems in clinical use. In short, although plasma p-tau217 is a promising non-invasive early detection method, healthcare professionals should still consider all the circumstances in the overall health status of each patient before making any decisions.

Theoretical and Natural ScienceVol. 206(1)
University College London (GB)
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon